FDA 483 - Dishman Carbogen Amcis Limited - October 26, 2018

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed four key deficiencies related to the facility's quality system and manufacturing processes.

Observation 1 indicates a failure to establish adequate procedures for the cleaning and maintenance of equipment, which is critical for preventing cross-contamination and ensuring product quality. Observation 2 highlights that the manufacturing process for "Drug X" was not adequately validated. This suggests a lack of documented evidence that the process consistently produces a product meeting its predetermined specifications and quality attributes.

Observation 3 points to insufficient controls to prevent contamination during the manufacturing process, posing a significant risk to product purity and patient safety. Finally, Observation 4 notes that the firm did not maintain proper records of batch production and control. This deficiency impacts traceability, quality assurance, and the ability to investigate deviations or product issues effectively.

These observations collectively indicate a need for significant improvements in the facility's quality management system, process validation, contamination control strategies, and documentation practices to ensure compliance with regulatory requirements and the production of safe and effective drug products.